M&A / Deals Beeline raises $300m for BMS drugs, and other biofinancings PharmaphorumBeeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.M&A / DealsRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week. M&A / DealsRead full story Post navigation Previous: Most patients “won’t see benefit” with Alzheimer’s drugsNext: Revolution doubles stock offering target to $2B following pancreatic cancer win Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
